LLY * Stock Overview
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Eli Lilly and Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13,339.00 |
| 52 Week High | US$13,844.99 |
| 52 Week Low | US$7,452.75 |
| Beta | 0.37 |
| 1 Month Change | 5.05% |
| 3 Month Change | 20.81% |
| 1 Year Change | 73.21% |
| 3 Year Change | 240.28% |
| 5 Year Change | 505.49% |
| Change since IPO | 1,981.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| LLY * | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | 6.6% | 4.3% | 0.2% |
| 1Y | 73.2% | -13.2% | 1.8% |
Return vs Industry: LLY * exceeded the MX Pharmaceuticals industry which returned -13.3% over the past year.
Return vs Market: LLY * exceeded the MX Market which returned 1.9% over the past year.
Price Volatility
| LLY * volatility | |
|---|---|
| LLY * Average Weekly Movement | 5.8% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in MX Market | 6.2% |
| 10% least volatile stocks in MX Market | 2.0% |
Stable Share Price: LLY * has not had significant price volatility in the past 3 months.
Volatility Over Time: LLY *'s weekly volatility (6%) has been stable over the past year, but is still higher than 75% of MX stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1876 | 43,000 | Dave Ricks | www.lilly.com |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.
Eli Lilly and Company Fundamentals Summary
| LLY * fundamental statistics | |
|---|---|
| Market cap | Mex$11.97t |
| Earnings (TTM) | Mex$104.51b |
| Revenue (TTM) | Mex$611.77b |
113.9x
P/E Ratio19.5x
P/S RatioIs LLY * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LLY * income statement (TTM) | |
|---|---|
| Revenue | US$35.93b |
| Cost of Revenue | US$7.13b |
| Gross Profit | US$28.80b |
| Other Expenses | US$22.66b |
| Earnings | US$6.14b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 08, 2024
| Earnings per share (EPS) | 6.82 |
| Gross Margin | 80.16% |
| Net Profit Margin | 17.08% |
| Debt/Equity Ratio | 204.3% |
How did LLY * perform over the long term?
See historical performance and comparison